Novo Nordisk (NVO) said Monday that Wegovy demonstrated a reduction in body mass index, or BMI, among children with obesity aged 6 to under 12 in a phase 3 trial.
When combined with a reduced-calorie diet and increased physical activity, semaglutide led to a 17.4% reduction in BMI compared with a 2.2% increase with placebo after 68 weeks, the company said.
The company added that 83% of children receiving semaglutide improved their BMI category, compared with 23.5% in the placebo group.
The results were presented at a scientific symposium during ObesityWeek 2026 and simultaneously published in The New England Journal of Medicine, the company said.
Price: 41.84, Change: +0.20, Percent Change: +0.49
Comments